Disclaimer: This is a demo and should not be used for actual decision-making.
ALCOHOL → CARDIOVASCULAR RISK

Alcohol guidance that follows survival, not slogans.

Komachi AI recommends an alcohol action - abstain, reduce, or maintain, drawn from an optimal treatment policy learned on longitudinal survival data, grounded in cardiovascular-prevention evidence, and checked by a clinical judge before it is shown.

Recommendation Judge: pass
Recommended actionReduce → abstain
+0.041Δ Sᵍ(τ)
0.27KL to π_β
3citations
Lightideal dose
−6.8%CVD risk Δ
4.4/5judge score
TrajectoryW, Lₜ, Aₜ
Policy actionSAC+BC
EvidenceRAG + cite
Judgesafety check

Illustrative sample output, no patient data.

THE PIPELINE

Four agents, one recommendation

A survival-derived policy proposes the action; an evidence layer grounds it; a clinical judge checks it before anything is shown.

Optimal policy

A KL-regularized SAC+BC policy learns the alcohol action that maximizes a survival-derived reward log(1 − λ), anchored to the behavior policy for offline credibility.

See the cohort

Recommender agent

An open-weights model, RL-posttrained against the Stage-1 survival reward, reads the individual trajectory and proposes the action in plain language.

Open chat

Evidence grounding

Retrieval over ACC/AHA, ESC, USPSTF, WHO and alcohol-specific guidance surfaces the passages behind each recommendation, with citations.

Open dashboard

Clinical judge

An LLM-as-judge scores every recommendation for clinical validity, evidence support, safety, and consistency with the policy before it is displayed.

Open dashboard
THE COHORT

Learned on NHEFS survival data

The policy is fit on the NHANES I Epidemiologic Follow-up Study - alcohol exposure and mortality tracked across four waves over two decades.

14,407
Subjects
NHEFS / NHANES I follow-up
τ = 4
Waves
1971–75 · 1982 · 1987 · 1992
2,298
CVD deaths
of 4,604 all-cause (ICD-9 390–459)
12
Guideline PDFs
ACC/AHA · ESC · USPSTF · WHO
THE TEAM

The people behind Komachi AI

A small group working at the intersection of causal inference, reinforcement learning, and clinical machine learning.

Toru Shirakawa

MD · PhD Student, Berkeley & UCSF

Toru Shirakawa is an MD and PhD student at UC Berkeley and UCSF, working on causal AI for long-term chronic disease management. He develops methods that turn longitudinal health trajectories into reliable, survival-informed treatment policies, bridging clinical medicine and machine learning, and is the lead author of the survival policy-learning framework that Komachi AI is built on.

Sylvia Cheng

PhD Student · UC Berkeley

Sylvia Cheng is a PhD student at UC Berkeley who likes developing ML models and causal methods to tackle real-world problems. Her research is driven by rich interests in applicable mathematical theory, such as dynamic treatment regimes via Targeted Maximum Likelihood Estimation, robust reinforcement-learning policy learning, and evolutionary game theory, which she brings together to make causal estimates trustworthy in practice.

Abhijith Varma Mudunuri

Researcher · UC Berkeley

Abhijith Varma Mudunuri is a Senior at UC Berkeley majoring in Data Science and Business. He works in the UC Berkeley / UCSF Department of Computational Precision Health under Prof. Ahmed Alaa on clinical machine learning, computer vision, and reinforcement learning, and is also a researcher with the Berkeley AI Research (BAIR) NLP Group under Prof. Alane Suhr, the Center for Targeted Machine Learning, and the Center for Edge Medicine.